Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Pacific Hematology Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Memorial Cancer Institute
mi
from
Hollywood, FL
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Memorial Cancer Institute
mi
from
Hollywood, FL
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Illinois Cancercare, Pc
mi
from
Peoria, IL
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Illinois Cancercare, Pc
mi
from
Peoria, IL
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Franciscan St. Francis Health, Site
mi
from
Indianapolis, IN
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Franciscan St. Francis Health, Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Crescent City Research Consortium, LLC
mi
from
Marrero, LA
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Crescent City Research Consortium, LLC
mi
from
Marrero, LA
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Northern Utah Associates
mi
from
Ogden, UT
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Northern Utah Associates
mi
from
Ogden, UT
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Ohio State University Medical Center
mi
from
Columbus, OH
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Local Institution
mi
from
Athens,
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Local Institution
mi
from
Athens,
Click here to add this to my saved trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Baptist Cancer Center
mi
from
Memphis, TN
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Baptist Cancer Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/16/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/16/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/16/2018
Houston Methodist
mi
from
Houston, TX
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/16/2018
Houston Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/16/2018
University of Arkansas
mi
from
Little Rock, AR
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/16/2018
University of Arkansas
mi
from
Little Rock, AR
Click here to add this to my saved trials
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/16/2018
City of Hope Medical Center
mi
from
Duarte, CA
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/16/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Children´s Hospital Los Angeles
mi
from
Los Angeles, CA
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Children´s Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
1st Allergy and Clinical Research Center
mi
from
Englewood, CO
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
1st Allergy and Clinical Research Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Allergy Associates of the Palm Beaches, PA
mi
from
North Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
University of South Florida; Asthma, Allergy & Immunology CRU
mi
from
Tampa, FL
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
University of South Florida; Asthma, Allergy & Immunology CRU
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Rush-Presbyterian-St. Luke's Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Children´s Hospital Boston
mi
from
Boston, MA
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Children´s Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Allergy, Asthma & Immunology Assoc.
mi
from
Omaha, NE
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Allergy, Asthma & Immunology Assoc.
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
The Asthma & Allergy Center, P.C.
mi
from
Papillion, NE
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
The Asthma & Allergy Center, P.C.
mi
from
Papillion, NE
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Pediatric Allergy/Immunology Associates
mi
from
Dallas, TX
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Pediatric Allergy/Immunology Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated:  1/16/2018
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders
Status: Enrolling
Updated: 1/16/2018
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
University of California San Diego Medical Center
mi
from
San Diego, CA
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
University of California at San Francisco
mi
from
San Francisco, CA
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Davis, Posteraro and Wasser, MDs, LLP
mi
from
Manchester, CT
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Davis, Posteraro and Wasser, MDs, LLP
mi
from
Manchester, CT
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Baptist Cancer Institute
mi
from
Jacksonville, FL
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Cancer Center of Florida
mi
from
Orlando, FL
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Cancer Center of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Georgia Cancer Specialists
mi
from
Atlanta, GA
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Georgia Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Karmanos Cancer Center, Wertz Clinical Cancer Center 4HWCRC
mi
from
Detroit, MI
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Karmanos Cancer Center, Wertz Clinical Cancer Center 4HWCRC
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Henry Ford Health System
mi
from
Detroit, MI
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Washington University School of Medicine - St Louis, MO
mi
from
Saint Louis, MO
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Washington University School of Medicine - St Louis, MO
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
New Mexico Oncology Hematology Consultants
mi
from
Albuquerque, NM
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
New Mexico Oncology Hematology Consultants
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Joan and Sanford I. Weill Medical College, Cornell University
mi
from
New York, NY
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Joan and Sanford I. Weill Medical College, Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Case Western Reserve University School of Medicine
mi
from
Cleveland, OH
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Case Western Reserve University School of Medicine
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Cleveland Clinic Foundation, Univ. of Ohio
mi
from
Cleveland, OH
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Cleveland Clinic Foundation, Univ. of Ohio
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated:  1/16/2018
Hematology Oncology Associates of South Texas
mi
from
San Antonio, TX
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension
Status: Enrolling
Updated: 1/16/2018
Hematology Oncology Associates of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53
Status: Enrolling
Updated:  1/17/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53
Status: Enrolling
Updated: 1/17/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Orange, CA
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Washington,
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Tampa, FL
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Boise, ID
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Boise, ID
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Detroit, MI
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Minneapolis, MN
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated:  1/18/2018
Novo Nordisk Investigational Site
mi
from
Columbus, OH
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Status: Enrolling
Updated: 1/18/2018
Novo Nordisk Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials